Chondroitin sulfate 846 epitope (CS846) can be used as a marker for newly synthesized aggrecan molecules in the matrix, and its presence in synovial fluid and serum can reflect the rate of aggrecan synthesis. The reactivity of CS846 was increased in human OA samples, where increased synthesis of aggrecan was generally observed. Creative BioMart Biomarker is capable to provide our customers with superior CS846 detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Introduction
Changes in the functional properties and disorders of articular cartilage in osteoarthritis (OA) are the result of changes in matrix macromolecular degradation, synthesis, structure and interaction. During the development of OA, changes occur not only in the degradation of matrix molecules, but also in the rate of synthesis and structure of various matrix components. These changes can represent the response of cells to joint and tissue damage and can serve as metabolic markers of tissue damage. The release of matrix macromolecular fragments and proteases following human OA or joint damage provides evidence of increased matrix turnover. Therefore, increased concentrations of fragmented type II collagen, aggrecan, cartilage oligomeric matrix protein (COMP), and bone sialoprotein (BSP) was detected in articular cartilage or synovial fluid of OA patients, accompanied by significant increase in matrix metalloproteinase 1 (MMP-1) and MMP-3 levels in synovial fluid. Aggrecan is a major component of the extracellular matrix (ECM) in cartilage and is a large proteoglycan. Aggrecan interacts with hyaluronan and link protein and forms large aggregated complexes that fill the interstices of the collagen meshwork. Aggrecan degradation is an important marker of OA, and CS846 is a marker of aggrecan synthesis. The level of CS846 is elevated in cartilage and synovial fluid of OA patients, and related to the progression of joint damage in rheumatoid arthritis (RA).
Figure 1. Structure of proteoglycan aggregates.
Application of CS846
- Serum, synovial fluid levels of CS846 can be used as biomarkers for the diagnosis of OA.
Our Advantages
- Accept a wide range of sample types
- Provide multiple detection methods, including ELISA, fluoro-microbeads guiding chip (FMGC)
- Ensure high sensitivity for detecting CS846 in different samples
- Ensure high accuracy and repeatable CS846 detection
- Ensure a wide kinetic range to detect samples of different concentrations
- Short experimental period
Workflow of CS846 Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the CS846 detection procedure to ensure high sensitivity, high accuracy and repeatable CS846 detection.
Please feel free to contact us if you would like to know more about CS846 detection. At Creative BioMart Biomarker, we not only provide high-quality CS846 detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
References:
- Lohmander, L.S.; et al. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum. 1999, 42(3): 534-44.
- Huang, K.; Wu L.D. Aggrecanase and aggrecan degradation in osteoarthritis. Journal of International Medical Research. 2008, 36: 1149.
- Jansen, W.D; et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum. 2009, 60(1): 290-8.
- Roughley, P.J.; Mort, J.S. The role of aggrecan in normal and osteoarthritic cartilage. Journal of Experimental Orthopaedics. 2014, 1: 8.
